Study Looking at Safety of Dacomitinib and How it Works in the Body in People with Livers that Do Not Work Properly

A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Plasma Pharmacokinetics and Safety of Dacomitinib in Participants With Severely Impaired Hepatic Function Relative to Participants With Normal Hepatic Function

Category & Conditions:
Cancer
Medicine:
VIZIMPRO® TABLETS(DACOMITINIB)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
A7471058
Open Plain Language Summary Result:Click here